UiPath Slides 24% After Q2 Earnings: Is PATH Stock a Buy?

UiPath shares dropped 24% following Q2 fiscal 2027 results that beat revenue expectations and included raised full-year guidance. Despite strong fundamentals including 12.5% ARR growth, fourth consecutive GAAP profitability, and AI appearing in 18 of 20 largest deals, investors focused on modest Q3 guidance and restrained ARR increases. Analysts view the selloff as creating an attractive entry point for patient investors, rating the stock a Buy.